Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
MBX Biosciences, Inc. shareholders approved Election of two Class II directors to serve for a three-year term ending at the annual meeting of stockholders to be held in 2029. at the 2026-06-04 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
The Company's stockholders voted on the following matters, which are described in detail in the Proxy Statement: (i) to elect two Class II director nominees, Patrick J. Heron. and Edward T. Mathers, to the Company's Board of Directors, each to hold office until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal ("Proposal 1") and (ii) to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 ("Proposal 2").
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
MBX Biosciences, Inc. shareholders approved Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-04 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
The Company's stockholders approved Proposal 2 to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 43,713,693 1,946 1,946 -
View on SEC.gov